Health Care [ 6/12 ] | Biotechnology [ 32/74 ]
NASDAQ | Common Stock
Zai Lab Limited develops and commercializes products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; VYVGART, a human IgG1 antibody fragment for myesthenia gravis; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; Qinlock to treat gastrointestinal stromal tumors; Xacduro, a combination of a beta-lactam antibiotic (sulbactam) and a beta-lactamase inhibitor (durlobactam) for the treatment of serious infections caused by acinetobacter; and Augtyro, a tyrosine kinase inhibitor ROS1 oncogenic fusions.
The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and its immunology, neuroscience, and infectious disease pipeline includes efgartigimod and xanomeline and trospium chloride.
It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO.
The company was incorporated in 2013 and is based in Shanghai, China.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 25 | -0.80 Increased by +20.00% | -0.63 Decreased by -26.32% |
| Nov 12, 24 | -0.42 Increased by +40.85% | -0.78 Increased by +46.15% |
| Aug 6, 24 | -0.80 Increased by +36.00% | -0.71 Decreased by -12.68% |
| May 8, 24 | -0.50 Increased by +1.96% | -0.92 Increased by +45.65% |
| Feb 27, 24 | -1.00 Decreased by -53.85% | -0.86 Decreased by -16.28% |
| Nov 7, 23 | -0.71 Increased by +57.74% | -1.04 Increased by +31.73% |
| Aug 7, 23 | -1.25 Increased by +13.19% | -0.79 Decreased by -58.23% |
| May 9, 23 | -0.51 Increased by +43.33% | -0.95 Increased by +46.32% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 109.07 M Increased by +65.68% | -81.68 M Increased by +14.40% | Decreased by -74.89% Increased by +48.34% |
| Sep 30, 24 | 102.27 M Increased by +47.72% | -41.67 M Increased by +39.74% | Decreased by -40.75% Increased by +59.21% |
| Jun 30, 24 | 100.50 M Increased by +45.95% | -80.28 M Increased by +33.60% | Decreased by -79.87% Increased by +54.50% |
| Mar 31, 24 | 87.15 M Increased by +38.78% | -53.47 M Decreased by -85.88% | Decreased by -61.36% Decreased by -33.94% |
| Dec 31, 23 | 65.83 M Increased by +5.16% | -95.43 M Decreased by -263.61% | Decreased by -144.96% Decreased by -245.77% |
| Sep 30, 23 | 69.23 M Increased by +20.31% | -69.15 M Increased by +56.50% | Decreased by -99.89% Increased by +63.84% |
| Jun 30, 23 | 68.86 M Increased by +42.94% | -120.89 M Increased by +11.15% | Decreased by -175.56% Increased by +37.84% |
| Mar 31, 23 | 62.80 M Increased by +34.40% | -28.77 M Increased by +66.08% | Decreased by -45.81% Increased by +74.76% |